Recombinant low virulence bovine herpesvirus-1 (BoHV-1) vaccine vectors
AssigneesThe State of Queensland Acting Through the Department of Agriculture and Fisheries, Meat & Livestock Australia Limited
InventorTimothy John Mahony
Life of this patent
Estimating the term…
Abstract
The present disclosure teaches generally in the field of vaccination and disease control in cattle and bovine animals. A recombinant bovine herpesvirus 1 (BoHV-1) vaccine vector is provided for efficient control of one or more bovine pathogens such as those associated with bovine respiratory disease complex, such as bovine viral diarrhea virus (BVDV), and which ameliorates disease conditions caused thereby. Protocols for the management of confined or herded bovine animals are also enabled herein.
Claims17
A vaccine against at least one antigen from a bovine pathogen, said vaccine comprising a bovine herpes virus-1 (BoHV-1) genome from a low virulence BoHV-1, said BoHV-1 having genetic material encoding the at least one antigen which is heterologous to the BoHV-1 genome inserted between two converging BoHV-1 genes, wherein the insertion does not substantially down-regulate expression of the BoHV-1 genes, wherein the genetic material encoding the at least one antigen is inserted between the polyadenylation signals of two converging genes selected from the group consisting of UL41 and UL40, UL36 and UL35, UL22 and UL21, UL19 and UL15, UL11 and UL10 and UL8 and UL7.
A method of producing a vaccine against at least one antigen from a bovine pathogen, said method comprising:
- (i) incorporating a BoHV-1 genome from a low virulence BoHV-1 into a bacterial artificial chromosome (BAC) vector to form a BoHV-1 pre-vector BAC construct;
- (ii) inserting genetic material encoding the at least one antigen into the BoHV-1 pre-vector BAC construct via an inducible recombination system to generate a recombinant BoHV-1-BAC (rBoHV-1-BAC) vector wherein the genetic material encoding the at least one antigen is inserted between the polyadenylation signals of two converging genes at a functionally equivalent site in another BoHV-1 to a site selected from the group consisting of between convergent genes UL41 and UL40, UL36 and UL35, UL22 and UL21, UL19 and UL15, UL11 and UL10 and UL8 and UL7;
- (iii) transforming and amplifying the rBoHV-1-BAC vector in a bacterial host;
- and
- (iv) purifying and isolating the rBoHV-1-BAC vector from the bacterial host and formulating the vector into a vaccine composition.
Dependencies are inferred from the claim text.